Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!
How is the Glioblastoma Multiforme (GBM) Treatment Market Expected to Expand from 2024 to 2033?
In recent times, there has been a swift expansion in the market size for the treatment of glioblastoma multiforme (gym). The market is projected to escalate from $2.23 billion in 2023 to $2.47 billion in 2024, with a compound annual growth rate (CAGR) of 10.6%. The surge within the historic period can be traced back to factors including a higher frequency of incidence and prevalence, upgrades in diagnostic methodologies, the influence of clinical trials and research funding, the establishment of collaborations and partnerships, and a more thorough comprehension of tumor biology.
The market size of the glioblastoma multiforme (gym) treatment is projected to undergo speedy expansion in the coming years and it’s predicted to reach $3.66 billion by 2028, proliferating at a compound annual growth rate (CAGR) of 10.3%. Reasons for growth in the predicted period include the rise of immunotherapies, advancements in precision medicine, enhanced awareness of genetic markers, amplified patient advocacy and awareness, as well as government backing for rare diseases. The anticipated period will also see major trends like the exploration of combination therapies, the deployment of artificial intelligence in diagnosing and planning treatment strategies, increased inclination towards immunotherapeutic methods, and advancements in medical tools and equipment.
Claim Your Free Sample of the Global Glioblastoma Multiforme (GBM) Treatment Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=8803&type=smp
What Influences Are Propelling the glioblastoma multiforme (gbm) treatment Market Forward?
As the frequency of brain disorders increases, the need for advancement in the glioblastoma multiforme (GBM) treatment market intensifies. Brain disorders involve irregular functionality of the brain, along with nerves across the human body and spinal cord. The rise in brain disorders such as glioblastoma multiforme (GBM), is associated with factors like an aging demographic, weakening immune systems, overdiagnosis, ionizing radiation, air pollution, etc. This amplifies the requirement for treating these disorders to elevate health conditions. For instance, Globocan, a US-based international organization offering global cancer stats, reported around 308,102 brain and central nervous system cancer cases and 251,329 deaths worldwide in 2020. Furthermore, a report from the American Cancer Society, a US-based voluntary healthcare organization aiming to eradicate cancer indicates that it’s estimated there will be 25,050 cases of malignant brain or spinal cord tumors diagnosed in the US in 2022. Therefore, the surging prevalence of brain disorders conclusively pushes the growth of the glioblastoma multiforme (GBM) treatment market.
What Key Segments Exist Within the Glioblastoma Multiforme (GBM) Treatment Market?
1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy
2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes
3) By Route of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers
What Trends Are Coming to the Forefront in the Glioblastoma Multiforme (GBM) Treatment Market?
Innovations in treatment approaches are becoming an increasingly important trend in the glioblastoma multiforme (GBM) treatment market. Key players in the market are dedicating resources to therapy research and development to maintain their competitive edge. For example, Daiichi Sankyo Company Limited, a pharmaceutical firm based in Japan, introduced DELYTACT, the first-ever oncolytic virus-based immunotherapy (Teserpaturev) for malignant glioma treatment, in November 2021. This was a collaboration with the Institute of Medical Science at The University of Tokyo. Oncolytic viruses are genetically engineered to infect and replicate only in cancer cells, leading to their destruction without affecting healthy cells or cell proliferation. The distinctive characteristics of DELYTACT (Teserpaturev) empower patients to produce immune-stimulating molecules or launch an anti-cancer immune response. This is achieved by activating the patient’s immune system’s multiple mechanisms and also has the ability to eradicate tumor cells that have metastasized to other brain regions.
Order Now for Fast Delivery of Your Glioblastoma Multiforme (GBM) Treatment Market Report!
What Regions Are Leading the Charge in the Glioblastoma Multiforme (GBM) Treatment Market?
North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The Glioblastoma Multiforme (GBM) Treatment Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the glioblastoma multiforme (gbm) treatment market, its market share, and analyzes key competitors along with their market positions.
The Table Of Content For The Glioblastoma Multiforme (GBM) Treatment Market Include
1. Glioblastoma Multiforme (GBM) Treatment Market Executive Summary
2. Glioblastoma Multiforme (GBM) Treatment Market Segments
3. Glioblastoma Multiforme (GBM) Treatment Market Size And Template Market Growth Rate
4. Key Glioblastoma Multiforme (GBM) Treatment Market Trends
5. Major Glioblastoma Multiforme (GBM) Treatment Market Drivers
……
25. Key Mergers And Acquisitions In The Glioblastoma Multiforme (GBM) Treatment Market
26. Top Glioblastoma Multiforme (GBM) Treatment Companies
27. Glioblastoma Multiforme (GBM) Treatment Market Opportunities And Strategies
28. Glioblastoma Multiforme (GBM) Treatment Market, Conclusions And Recommendations
29. Appendix
Discover Related Reports by The Business Research Company:
Neurology Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report
Neuroprosthetics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report
Neurostimulation Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neurostimulation-devices-global-market-report
Learn More About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
